Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's President and CEO, Jayson Rieger, PhD, MBA, will engage in a fireside chat during the event.
The virtual presentation is scheduled for Tuesday, April 8, 2025, at 1:30 pm ET. Interested participants can access the live webcast through a provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event, which runs from April 7-10, 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Noah L. Rosenberg, M.D. as Chief Medical Officer. Dr. Rosenberg brings over 30 years of clinical and therapeutic development experience, with multiple global drug approvals including dermatology treatments.
Dr. Rosenberg succeeds Gary Goldenberg, who will continue as a strategic advisor after overseeing the FDA approval of YCANTH® for molluscum contagiosum treatment. In his new role, Rosenberg will focus on establishing YCANTH® as the standard care for molluscum contagiosum and advancing clinical programs in basal cell carcinoma and common warts.
As part of his appointment, Dr. Rosenberg received an inducement grant of stock options to purchase 325,000 shares at $0.5221 per share, vesting over four years with initial 1/8th vesting after six months.
Verrica Pharmaceuticals (VRCA) reported Q4 and full-year 2024 results, highlighting a 12.3% quarterly growth in YCANTH® dispensed applicator units to 8,654 in Q4'24. The company achieved positive quarterly revenue earlier than expected and implemented significant cost reductions, targeting cash-positive monthly operating results by end of 2025.
Q4 2024 financial results showed product revenue of $0.3M (down from $1.9M in Q4 2023), with reduced operating expenses. Full-year 2024 results included product revenue of $6.6M (up from $4.7M in 2023). The company reported a net loss of $76.6M for 2024.
Key developments include: a $42M public offering in November 2024, strengthening the balance sheet; advancement of late-stage pipeline programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH); and introduction of a new single applicator configuration in Q1 2025. The company ended 2024 with $46.3M in cash and cash equivalents.
Verrica Pharmaceuticals (Nasdaq: VRCA) has scheduled its Q4 and full-year 2024 financial results conference call and webcast for March 11, 2025, at 4:30 p.m. ET. The dermatology therapeutics company will present financial performance data and provide a corporate update during the event.
Participants can join via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) using conference ID: VERRICA. The webcast will be accessible through the company's investor relations website section, with a replay available for 90 days post-event.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston. Jayson Rieger, PhD, MBA, President and CEO, will engage in a fireside chat at the event.
The presentation is scheduled for Monday, March 3, 2025, at 2:30 pm ET in Boston, MA. Interested participants can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event.
Verrica Pharmaceuticals (NASDAQ: VRCA) presented three posters featuring clinical data from Part 2 of their Phase 2 study of VP-315, a novel oncolytic peptide for treating basal cell carcinoma (BCC), at the 2025 Winter Clinical Dermatology Conference. The study, involving 82 patients with 91 tumors, demonstrated a 97% Calculated Objective Response Rate.
Key findings include: 51% of tumors achieved complete histological clearance, while remaining patients showed an average 71% reduction in tumor size. The treatment showed favorable safety profiles with no Treatment Related Serious Adverse Events, and mostly mild to moderate adverse events.
The company plans to request an End-of-Phase 2 meeting with the FDA in first half of 2025, with genomic and T-cell data expected in Q1 2025. Verrica believes VP-315 could serve as a first-line therapy in both primary and neoadjuvant settings, potentially representing a multi-billion-dollar opportunity as a non-surgical alternative for BCC patients.
Verrica Pharmaceuticals (NASDAQ: VRCA) reports positive momentum in Q4 2024, with YCANTH dispensed applicator units surpassing the previous quarter's numbers despite cost reductions. The company notes significant reduction in distributor inventory levels and plans to launch a single applicator configuration in Q1 2025 to enhance accessibility and reduce costs for physician practices.
The company is expanding distribution through local independent pharmacies while implementing targeted cost management. The new single applicator packaging aims to facilitate initial purchases and increase patient access through buying groups, hospitals, and government entities. Verrica continues to advance its pipeline, including YCANTH for common warts in partnership with Torii Pharmaceutical, and VP-315, an oncolytic peptide showing promising Phase 2 results for basal cell carcinoma treatment.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced the granting of a nonqualified stock option to its new Chief Operating Officer, David Zawitz. The grant includes options to purchase 950,000 shares of common stock under the Company's Inducement Plan, effective December 9, 2024.
The stock option, granted as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4), will have an exercise price equal to the closing price of Verrica's common stock on December 9, 2024. The vesting schedule includes 1/8th of shares after six months and 1/48th monthly thereafter, subject to continuous service.
Verrica Pharmaceuticals announced that its partner Torii Pharmaceutical has submitted a New Drug Application (NDA) for TO-208 to treat Molluscum Contagiosum in Japan. TO-208, marketed as YCANTH® in the U.S., demonstrated superiority to vehicle in Phase 3 clinical studies with Japanese patients aged ≥2 years, showing a safety profile consistent with U.S. studies.
The development addresses an estimated 1.6 million cases of molluscum in Japan, representing a significant unmet medical need. This submission follows Torii's exclusive license agreement with Verrica in March 2021 for development and commercialization in Japan. Notably, VP-102 received U.S. approval in July 2023 and has been marketed as YCANTH® since August 2023.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced the pricing of a $42.0 million public offering. The offering includes 44,964,045 shares of common stock and pre-funded warrants to purchase 2,235,955 shares. Additionally, the offering includes Series A warrants to purchase 23,600,000 shares at $1.0680 per share and Series B warrants for 23,600,000 shares at $1.3350 per share. The combined offering price is $0.89 per share with accompanying warrants. Jefferies is serving as the sole book-running manager, and the offering is expected to close on November 22, 2024.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
